How This Evidence Evolved
ICU Glucose Control
The pendulum swings
Timeline
Early observations and pilot data that first suggested a new direction
Landmark RCTs and pivotal trials that established the evidence base
Hospital mortality: intensive 37.3% vs conventional 40.0% (P=.33); morbidity benefit with ICU stay≥3 days
Stopped early for protocol violations; ICU death: IIT 17.2% vs intermediate 15.3%; hypoglycaemia 8.7% vs 2.7%
Follow-up studies, subgroup analyses, and real-world validation
Integration into clinical practice guidelines and recommendations
For adults with sepsis or septic shock, initiate insulin at glucose ≥180 mg/dL (strong recommendation); typical target after initiation 144–180 mg/dL.
Current standard of care and ongoing research directions
ICU discharge alive with tight vs liberal glucose control: HR 1.00, 95% CI 0.96–1.04; P=.94
Survival at 90 days: individualized 67.2% vs conventional 69.6% (95% CIs 64.2–70.3 and 66.7–72.5)
Time in 6–8 mmol/L target over 48 hours: closed-loop 54.3% vs local protocol 18.5% (P=.001)
Time in target during ICU monitoring: CGM 33.23% vs conventional 26.26%
Association of glucose-variability metrics with short-term mortality; abstract omits pooled effect estimates
Landmark Trials in This Story
Intensive insulin therapy in critically ill patients
ICU mortality 4.6% vs 8.0%, p<0.04
Intensive insulin therapy in the medical ICU
Hospital mortality: intensive 37.3% vs conventional 40.0% (P=.33); morbidity benefit with ICU stay≥3 days
A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study
Stopped early for protocol violations; ICU death: IIT 17.2% vs intermediate 15.3%; hypoglycaemia 8.7% vs 2.7%
Intensive versus conventional glucose control in critically ill patients
90-day mortality 27.5% vs 24.9%, OR 1.14 (95% CI 1.02–1.28), p=0.02
In-Hospital Management of Hyperglycemia: The Role of Insulin Degludec.
Narrative review reports ADA 2025 ICU glucose targets and selected surgical-patient exceptions; not an ICU insulin-degludec trial.
Tight Blood-Glucose Control without Early Parenteral Nutrition in the ICU.
ICU discharge alive with tight vs liberal glucose control: HR 1.00, 95% CI 0.96–1.04; P=.94
Individualised versus conventional glucose control in critically-ill patients: the CONTROLING study-a randomized clinical trial.
Survival at 90 days: individualized 67.2% vs conventional 69.6% (95% CIs 64.2–70.3 and 66.7–72.5)
Feasibility of fully automated closed-loop glucose control using continuous subcutaneous glucose measurements in critical illness: a randomized controlled trial.
Time in 6–8 mmol/L target over 48 hours: closed-loop 54.3% vs local protocol 18.5% (P=.001)
Clinical validation of continuous glucose monitoring in glycemic management of critically ill sepsis patients: A prospective randomized clinical study.
Time in target during ICU monitoring: CGM 33.23% vs conventional 26.26%
Glycemic Variability As a Prognostic Factor for Mortality in Patients With Critical Illness: A Systematic Review and Meta-Analysis.
Association of glucose-variability metrics with short-term mortality; abstract omits pooled effect estimates
Explore the evidence yourself
Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.